Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lopinavir Saquinavir

Nevirapine is a moderate inducer of CYP3A metabolism, resulting in decreased levels of amprenavir, indinavir, lopinavir, saquinavir, efavirenz, and methadone (Table 49-4). Drugs that induce the CYP3A system, such as tipranavir, rifampin, rifabutin, and St. John s wort, can decrease levels of nevirapine, whereas those that inhibit CYP3A activity, such as fluconazole, ketoconazole, and clarithromycin, can increase nevirapine levels. [Pg.1080]

PROTEASE INHIBITORS ANTIHISTAMINES-ASTEMIZOLE, CHLORPHENAMINE, TERFENADINE Possibly t adverse effects with amprenavir, atazanavir, indinavir, ritonavir (with or without lopinavir), saquinavir and tipranavir Inhibition of CYP3A4-mediated metabolism of astemizole the risk is greatest in patients who are slow CYP2D6 metabolizers because chlorphenamine and terfenadine are also metabolized by this route Avoid co-administration... [Pg.618]

The data on the effect of protease inhibitors on ketoconazole are more limited. Amprenavir caused a modest increase in ketoconazole levels, and the UK manufacturer of amprenavir suggests that no ketoeonazole dose adjustment is necessary with amprenavir alone, although the US manufacturer recommends increased monitoring for adverse effeets and states that a dose reduction may be needed in patients receiving ketoconazole in doses of more than 400 mg daily. However, a marked effect was seen for ritonavir alone and for ritonavir combined with darunavir, fosamprenavir, lopinavir, saquinavir and theoretically tipranavir. This may increase the adverse effects of ketoconazole. Most protease inhibitor manufacturers say that doses greater than 200 mg a day of ketoconazole are not recommended. Similarly, the UK manufacturers of ketoconazole and ritonavir say that a dose reduction of ketoconazole should be considered when it is given with ritonavir. ... [Pg.815]

Justesen, U.S. Pedersen, C. KUtgaard, NA. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelflnavir and the nelflnavir active metabolite M8 in plasma by liquid chromatography, J.Chromatogr.B, 2003, 783, 491-500. [Pg.39]

Tribut, O. Arvieux, C. Michelet, C. Chapplain, J.-M. Afiain, H. Bentue-Ferrer, D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography, Ther.Drug Monit., 2002, 24, 554-562. [nevirapine efavirenz indinavir amprenavir nelfinavir ritonavir lopinavir saquinavir]... [Pg.40]

Monit, 2002, 24, 554-562. [LOQ 25 ng/mL nevirapine efavirenz indinavir amprenavir nelfinavir ritonavir lopinavir saquinavir]... [Pg.439]

Protease inhibitor drugs as amprenavir, nelfinavir, indinavir, lopinavir, saquinavir, ritonavir, and atazanavir, and nonnucleoside reverse transcriptase inhibitors drugs nevirapine and efavirenz... [Pg.269]

Zidovudine Didanosine Stavudine Lamivudine Abacavir Tenofovir Emtricitabine Nevirapine Efavirenz TMC125 Saquinavir Indinavir Lopinavir Fosamprenavir Atazanavir Tipranavir Darunavir Raltegravir Elvitegravir Enluvirtide Maraviroc Vicriviroc Bevirimat... [Pg.335]

Tenofovir + Emtricitabine Zidovudine + Lamivudine Abacavir + Lamivudine Efavirenz or Nevirapine Lopinavir/r or Atazanavir/r or Eosamprenavir/r or Saquinavir/r... [Pg.336]

APV, amprenavir ATV, atazanavir CNS, central nervous system CVD, cardiovascular disease D/C, discontinue ddC, zalcitabine ddl, didanosine DEXA, dual-energy x-ray absorptiometry d4T, stavudine EFV, efavirenz HDL, high-density lipoprotein HIV, human immunodeficiency virus HTN, hypertension IDV, indinavir LDL, low-density lipoprotein LPV/r, lopinavir+ ritonavir MRI, magnetic resonance imaging NNRTI, nonnucleoside reverse transcriptase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NVP, nevirapine PI, protease inhibitor RTV, ritonavir SQV, saquinavir TDF, tenofovir disoproxil fumarate TG, triglyceride TPV/r, tipranivir + ritonavir ZDV, zidovudine. [Pg.1273]

Protease inhibitors (amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir) Rifampin... [Pg.350]

Azalides azithromycin Azoles fluconazole, itraconazole, ketoconazole, and voriconazole Macrolides erythromycin, clarithromycin Protease inhibitors amprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, and saquinavir Quinolones ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin. [Pg.396]

Fewer head-to-head data with oncedaily fosamprenavir-ritonavir and lopinavir ritonavir, as well as saquinavir (Invirase) + ritonavir... [Pg.452]

Cross-resistance Cross-resistance among Pis has been observed. Tipranavir had less than 4-fold decreased susceptibility against 90% (94 of 105) of HIV-1 isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir. Tipranavir-resistant viruses that emerged in vitro had decreased susceptibility to the Pis amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, and ritonavir but remained sensitive to saquinavir. [Pg.1814]

This class of antiretrovirals may be considered the most potent therapeutic agents for HIV to date. Protease inhibitors are used in combination regimens and combinations of reverse-transcriptase inhibitors and protease inhibitors have been proven most effective to decrease viral load and prolong survival. However, the protease inhibitors generally show poor penetration into the CNS and thus have no effect on aids dementia. The present Pis available for the treatment of HIV are indinavir, ritonavir, nel-finavir, saquinavir and (fos)amprenavir, atazanavir and lopinavir (in combination with ritonavir as ritonavir improves the bioavailability of lopinavir by inhibiting its metabolism in the liver by CYP3A). [Pg.422]

TC Lamivudine ABC Abacavir d4T Stavudine ddC Zalcitabine ddl Didanosine TDF Tenofovir ZDV Zidovudine, also abbreviated as AZT FTC Emtricitabine NVP Nevirapine DLV Delavirdine EFV Efavirenz RTV, r Ritonavir Pl/r Ritonavir boosted protease inhibitor SQV Saquinavir IDV Indinavir LPV Lopinavir NEV Nelfinavir APV Amprenavir ATV Atazanavir DRV Darunavir... [Pg.550]

Agents within the group of protease inhibitors are nelfinavir (NFV), indinavir (IDV), lopinavir (LPV), saquinavir (SQV), (fos)amprenavir (APV),... [Pg.550]

Ritonavir Amprenavir Indinavir Lopinavir Nelfinavir Saquinavir ... [Pg.591]

Similar labeling language also in the labeling of INVIRASE (Roche Laboratories) (saquinavir mesylate) capsules, December 2003 KALETRA (Abbott) (lopinavir/ritonavir) capsules, (lopinavir/ritonavir) oral solution, February 2004 and LEXIVA (GlaxoSmithKline) (fosamprenavir calcium) tablets. May 2004. [Pg.258]

Etravirine Delavirdine, efavirenz, lopinavir/ritonavir, nevirapine, ritonavir, tipranavir Darunavir, saquinavir, tenofovir... [Pg.1077]

Fosamprenavir Abacavir, atazanavir, delavirdine, etravirine, indinavir, lopinavir, ritonavir, tipranavir, zidovudine Didanosine, efavirenz, nevirapine, saquinavir... [Pg.1077]

See other pages where Lopinavir Saquinavir is mentioned: [Pg.746]    [Pg.49]    [Pg.1816]    [Pg.589]    [Pg.589]    [Pg.614]    [Pg.617]    [Pg.1060]    [Pg.198]    [Pg.438]    [Pg.746]    [Pg.49]    [Pg.1816]    [Pg.589]    [Pg.589]    [Pg.614]    [Pg.617]    [Pg.1060]    [Pg.198]    [Pg.438]    [Pg.199]    [Pg.89]    [Pg.89]    [Pg.516]    [Pg.351]    [Pg.63]    [Pg.82]    [Pg.279]    [Pg.86]    [Pg.589]    [Pg.119]    [Pg.1077]   
See also in sourсe #XX -- [ Pg.822 ]



SEARCH



Lopinavir

© 2024 chempedia.info